Tài liệu, văn bản bạn tìm kiếm
Certain comorbidities, Hematopoietic malignancy, Dismal outcome, Disease monitoring, Predominantly fair-skinned, Cell adhesion-related glycoproteins MUC-1, Abdominal cancers, Nuclear factor rythroid 2-related factor 2, Radiotherapy fraction, Exogenous stresses, TNF-related apoptosis inducing ligand, Therapeutic options, Doxorubicin either, Recombinant granulocyte-colony stimulating factor, Docetaxel chemotherapy, Intensified neoadjuvant radiochemotherapy, Cancer related survival, Global hypomethylation, Plasma S-adenosylmethionine, Trained dogs, Including physical, Consequently increasing survival, Direct bisulfite sequencing, Temporal lobe injury, Acid-prepared mesoporous silica, Malignant mesotheliomas, Chemoresistant tumors, Basal phenotype, Mammary adenocarcinoma, Pain diagnosis, Luminex assay, Biomarker validation, High mammographic density, Integrin alpha3, Integrin beta4, Multiplex analysis, Adherence rates, Definite chemoradiotherapy, Complete histological response, Low cell counts, Operative morbidity, M2 macrophages contribute, Serum metabolite biomarkers, Tumor proliferation, Symptom index, Tumor incidence, Ovarian origin, HPV-mediated transformation, Differentiation resistant phenotype, Periampullary adenocarcinomas, Distal bile duct, Duodenal adenocarcinoma, Embryologic origin, Lanreotide autogel, Antiproliferative effect, Transcribed ultra-conserved regions, Ultra-conserved regions, ATRA-responsive cell lines, Excision repair cross-complementation group 1, Hepatocyte nuclear factor 4alpha, Thymosin β10, Bone morphogenetic protein 4, EGFR 3′ untranslated region, Matrigel provides, CRC cell lines, Adrenocortical carcinomas, Small-scale randomized clinical trial, TP53 gene, Promote malignant, Oncogenic factors secreted, Tumor cell-secreted factors, Ubiquitin-conjugating enzyme 2C, Absolute rates, Presenting estimates, Non-coding RNA over-expressed, Potential disease-specific biomarker, Corticotropin releasing factor, Deleted in liver cancer 1, Growing rapidly, Proximal tubules, CRHBP protein, Cholinergic agonist, Detached mindfulness, Mesothelial origin, Co-morbidity, Tankyrase inhibitors, β-catenin mutations, Kinase and phosphatase inhibitors, Early pneumothorax, ALK rearranged lung adenocarcinoma, Bahraini women, Scarce information, Certain breakdown, Tumor blood vessels, Hypoxia occurs, Certain molecular features, Significant hypoxia, NFκB pathways, Malignant peripheral nerve sheath tumor, Invasive phenotype, Imatinib mesylate inhibits cell growth, Resistant cell lines, Crypt growth factors, Receptor-β, Racial disparity, Lymphomas including Hodgkin’s, Odontogenic Ameloblast-associated Protein, Vascular endothelial growth, Carcinogenic exposure, Neoplastic tissues, Haematopoietic malignancies, Potential carcinogens, Cellular growth, Acute skin damage, Cisplatin combination, Individual’s susceptibility, Single-locus analysis, Estrogen receptor pathway, Gallbladder toxicity, Soy phytoestrogens, Refractory to aromatase inhibitor, Including cholecystitis, Recurrent mutations, IGF1R signaling, Metabolite equol, Overall meta-analysis, Biliary colic, Asturian population, Non-steroidal aromatase inhibitor, Bone neoplasm, Gallbladder enlargement, High-grade osteosarcoma, Invasive cervical carcinoma, Follicle-stimulating hormone receptor, High-grade astrocytomas, Cox-2 inhibitor celecoxib, Aggressive malignant brain tumors, Skeletal mineralization, Gastric cardia adenocarcinoma, Promoter’s methylation prior, PDAC-phenotypes, Anaplastic lymphoma kinase gene, Epithelial capsules, Long interspersed nuclear element-1 endonuclease, Q methodology, GCRG213 protein, Non-disrupted capsule, Sexual wellbeing, Tight junction protein, NOTCH1 mutations, Src kinase, Mechanism of inhibition, Anti-VEGF antibody, Separating patients treated, Piagnostic accuracy, Epidermal barrier function, Treating urothelial cancer, Claudin 1 protein, Describe factors, Multiple signal pathways, Anti-bacterial prophylaxis, 1-hydroxypyrene glucuronide, Diffuse reflectance imaging, Extracellular matrix structure, Nuclear changes, Proliferation assays, Rhabdoid tumors, Chemotherapy necessitating, HDAC-inhibitors plus fenretinide, Aggressive neoplasm, Accurate prognostic, Prognostic tumor biomarkers, Increasing incidence rate, Complete prevalence, 70-gene signature, Salted fish consumption, Vitamin D analogs, Metastasis-related genes, G2/M DNA-damage checkpoint, SIRT1 up-regulation, Complex health problems, Acquire mesenchymal, Ultrasonic spectrum analysis, Unnecessary chemotherapy, Biologically distinct subgroups, Young breast cancer, Underlying clinical significance, ESCC cell growth, Musculoskeletal sarcoma, NDRG2-negative patients, Neural-cadherin, Tissue morphogenesis, Metastasis-free survival rate, Seborrheic keratosis, Epigenetic reprogramming, Pluripotency-related pathways, Frizzled-8, Wnt-2, Germ line mutations, Plausible candidate, Simultaneous modulated accelerated radiotherapy, Prokaryotic organisms, Boost technique, Low self- motivation, N-terminal methionine excision, Cervical lymph nodes, Human mitochondrial peptide deformylase, Transcription activity, Epstein-Barr virus–associated malignancy, Definitive treatment eventually, Radioresistant NPC cell line, Molecular therapeutic, Hypoxic incubator, Partial oxygen deprivation, Decreased oxygenation, Low-dose, Excluding nasopharynx, Obesity-associated gene, Sexual hygiene, Cancer-associated anemia, Non-thyroidal illness syndrome, DNA-damaging drugs, Low hemoglobin, Roslin 2, Therapeutically challenging malignancies, First-degree relatives, Cancer patient survival, Dual-luciferase assays, Anthracycline treatment, Hematopoietic factor, Individual cancers, Metropolitan areas, BRCA1/2 mutation carriers, Haematopoietic tissues, African men, Melanoma therapy, External beam RT, Mutated BRAF gene, Humanized KS-interleukin-2, Immunologic activity, Aggressive tumor, Hemithoracic radiation, Pathological pregnancy, Choriocarcinoma via regulation, Anti-apoptotic protein Bcl-2, Potentially interesting diagnostic factor, Gestational trophoblastic tumor, Choriocarcinoma cell lines, Osteolytic bone disease, Therapeutics entering, Chronic administration, Residual cancer cells, Gefitinib maintenance treatment, Cytostatic concentrations, Metastatic cancer cells, Gene electrotransfer, Promoting oncogenicity, HAT inhibitor, Tumor treatment, Radiation treatment of sarcomas, Acetylated H4K16, HER targeted therapy, Trimethylated H4K20, Luminal subtype, Microarray gene expression analysis, Chemotherapeutic failure, EGFR ligands, Adjacent nonmalignant, PI3K gene mutations, Gene over-expression, Eloquent tumor, Anaplastic astrocytomas, Primary invasive breast cancer tumors, Matricellular glycoprotein, Non-serosa-invasive, Pediatric leukemia, Congenital acute lymphoblastic leukemia, Cytokine secretion profiles, NF-κB signaling pathway, Rib fracture, Chest wall injury, Class III beta-tubulin, Matrix metalloproteinase 14, Specificity protein 1, Prognostic indexes, Biological subtype, PRL-3 phosphatase, Human ERBB2 gene, Cancer biotherapy, 2-Methoxyestradiol, Aberrant splicing, Microtubule-targeting agents, Microtubule-targeting anthelmintic, Limulus amebocyte lysate, Human CRC liver metastases, Cell stress, Transposon mutagenesis, Fail miserably, Human PDAC cell lines, Involve diverse, Systematically discover, Barcode multiplexing, F-fluorodeoxyglucose, Radioguided surgery, Gamma detection probes, Atypical teratoid rhabdoid tumor, Histological differentiation, Malignant rhabdoid tumors, Trinucleotide repeat containing 6B, Rhabdoid tumor predisposition syndrome, Cisplatin-based regimen containing S-1, Weekly docetaxel, Primary malignant tumors, Atomic spectrometry, Potential environmental hazard, Aluminum concentrations, Enormous public health, Stable diseases, Progressive diseases, pithelial-mesenchymal transition, Sociodemographic indicators, Arsenic-contaminated, Cell-based assay system, Bladder calculus, Rapid screening bioassay, TRPC6 gene, Bladder outlet obstruction, Epigenetic drug model, PEGylated liposomes, Treatment beyond progression, Fluoropyrimidine-containing chemotherapy, Thrombopoietin receptor agonists, Chemotherapyinduced thrombocytopenia, Vitamin D transcriptional, Histone H3 phosphorylation, Epstein-Barr virus latent membrane protein-1, Neoplastic cell transformation, Time-dependent endpoint, Vaccine treatment, Progesterone treatment, Salivary biomarker, VEGF receptor-tyrosine kinase inhibitor, Overall tumor, Unacceptable toxicity, Lymph node excision, Androgen suppression therapy, Orphan receptor, Multiple biological, Lamina attachment domains, Iron containing, Insulator regions, Wnt-signalling cascade, PSA-Recurrence, Aggressive primary tumor, Cell cycle dynamics, Non-histone heterochromatic protein, Carbon ion irradiation, Early and late apoptosis, P53-independent-apoptosis, Hsp90 inhibitor, Phase I study, Escalating ganetespib, BRCA1 protein, Type IV collagen, Basement membrane, Integrin receptors, Autocrine loop, Cdk4 inhibition, Chemoprevention strategy, Phosphorylating retinoblastoma, Cdk4 pathway, High grade dysplastic nodules, Advanced lung cancer inflammation index, Well-differentiated hepatocellular carcinoma, Weekly schedule, Aminoacylase-1, Radiotherapy breast cancer, Quality of life questionnaire-core, 3-weekly schedule, Sequestosome-1, Subject significance questionnaire, Minimal clinically important differences, Dock-and-Lock, Tumors harbor, Insulin-like growth factor-I receptor, Membrane type 1 matrix metalloproteinase, Emerging observations indicate, Flaxseed lignan complex, Peripheral blood leukocytes, Radiation pneumonopathy, Leukocytes play, Plasma protein, Chemotherapyassociated neutropenia, Radiation dispersion device, Notch-3 expression, Fighting cancer, Incidental radiation, Metabolite diffusion, Inhaled radioisotopes, Bile duct